https://rijournals.com/public-health-and-pharmacy/

RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(2): 49-52, 2024

RIJPP Publications ISSN ONLINE: 1115-8689

ISSN PRINT 1597-8559

https://doi.org/10.59298/RIJPP/2024/3234952

The Role of Genomics in Infectious Disease Control

Nyiramana Mukamurera P.

Faculty of Medicine Kampala International University Uganda

ABSTRACT

The integration of genomics into infectious disease control has revolutionized pathogen detection, surveillance, and treatment strategies. With advancements in next-generation sequencing (NGS), genomic technologies have enabled the identification of infectious agents, tracing their transmission, and monitoring of antimicrobial resistance. Genomic epidemiology offers a powerful tool for outbreak investigations by identifying transmission chains and understanding pathogen evolution. Furthermore, genomics supports precision medicine, allowing for tailored treatments based on both pathogen and host genomes. This paper reviews the applications of genomics in disease detection, outbreak management, antimicrobial resistance surveillance, and precision medicine, underscoring its pivotal role in global public health efforts. The future of infectious disease control will be shaped by genomics, with an emphasis on enhanced diagnostics, personalized treatment, and real-time pathogen tracking.

Keywords: Genomics, Infectious Diseases, Next-Generation Sequencing, Outbreak Investigation, Genomic Epidemiology.

INTRODUCTION

Genomics, the study of an organism's entire genome including genes and their functions as well as interrelationships, has revolutionized the understanding of infectious diseases. The introduction of next-generation sequencing technologies has significantly advanced our ability to investigate infectious diseases at individual and population levels. In the past, traditional microbiological approaches such as culture and phenotypic identification were destructive and time-consuming; however, with the development of NGS, large amounts of short reads from the DNA or RNA of a pathogen can be rapidly obtained and analyzed. The increased generation of microbial genomic data has allowed the identification of pathogens at the molecular level and assessed their presence in clinical samples, cultured isolates, and the environment. Incorporation with strengthened epidemiological methods, such as case investigations, and genetic analysis can be complementary to traditional methods [1, 2]. For human health, genomic data is critical for identifying transmission clusters, outbreaks, or chains of transmission that are difficult to differentiate with traditional epidemiological methods. Furthermore, the history and movement of a pathogen can be broadly reconstructed by examining genomic data, including spatial and temporal patterns of transmission, evolutionary trends, and how human interventions, natural events, and hosts have shaped the spread of the pathogen. Obtaining information from the genomics of a pathogen can aid public health responses to infectious diseases by allowing the rapid identification and characterization of the aetiological agent, coordinating management practices, implementing preventive measures, and guiding national and international public health efforts. This section will give the reader a brief overview of this paper and describe rapid advancements in the application of genomics to infectious disease investigations. The subsequent sections will provide a more detailed discussion of the role of genomics in a range of infectious diseases [3, 4].

GENOMIC TECHNOLOGIES FOR INFECTIOUS DISEASE DETECTION AND SURVEILLANCE

Genomics and other omics technologies are playing an increasingly important role in the detection, surveillance, and control of infectious diseases. Whole-genome sequencing and the development of highly accurate or 'point-of-need' pathogen detection with polymerase chain reaction are currently the most important technologies used for the fast and accurate detection of pathogens. Whole-genome sequencing can also be used to identify agents for which no PCR test is available and to differentiate between subtypes of pathogens that differ in pathogenicity and virulence. In addition to using genomics for outbreak investigation, genomics data are increasingly integrated into clinical care, diagnostics, and public health surveillance of infectious diseases. The use of genomics to integrate pathogen detection, outbreak investigation, and public health is advancing rapidly and promises to revolutionize infectious disease control. Using either distinct genome sequences or the associated clinical and epidemiological metadata, genomics can be used to identify emerging infectious diseases, monitor known pathogens, and track the spread of infections [5, 6]. High-throughput sequencing platforms and bioinformatic workflows have made it increasingly easier to utilize genomic technology in real-time disease surveillance, and across political and geographical boundaries. Several international genomic surveillance systems have been set up and are changing the field of infectious diseases. Despite the rapid advances in the detection and surveillance technologies of infectious disease agents, there are many challenges that limit their implementation in settings with limited resources. This paper discusses recent advances in the use of genomics in the management of infectious diseases and emphasizes the increasingly important role of genomics in managing new infectious diseases [7, 8].

GENOMIC EPIDEMIOLOGY AND OUTBREAK INVESTIGATION

Genomic epidemiology and outbreak investigation. Genomic epidemiology represents a crucial complement to interpreting and understanding epidemiological disease dynamics and history and to perform adequate outbreak investigations, including determining the source of the outbreak, transmission dynamics, and testing genotype-phenotype associations. Consequently, this gives the possibility to trace the evolution and spread of the pathogens causing an outbreak and linking clinical and epidemiological data to understand outbreak characteristics. Genomic epidemiology can provide valuable information based on both isolates or samples collected during human or food surveillance. Genomic datasets for human and food/animal isolates collected using systematic surveillance can also inform when an outbreak starts [9, 10]. In a recent international forum that summarized and shared data from retrospective and prospective studies using genome sequencing and genomic epidemiology as a tool for outbreak investigations, successful examples were provided of tracing, in small to large, simple to complex, foodborne, waterborne, healthcare-associated, and environment-associated outbreaks. One of the studies was performed on a methicillin-resistant Staphylococcus aureus outbreak at a hospital. Some other studies demonstrated support in outbreak investigation and identifying transmission chains by the genomes of Escherichia coli causing urinary tract infections, Campylobacter jejuni, and Listeria monocytogenes, and MCR- and ESBL-producing E. coli isolates, including a concurrent outbreak of VIM-producing Pseudomonas aeruginosa detected in ten European countries [11, 12].

GENOMIC SURVEILLANCE OF ANTIMICROBIAL RESISTANCE

Antimicrobial resistance (AMR) can sometimes compromise effective disease control. Genomic surveillance has the potential to improve how we monitor AMR in different pathogens. Genomic studies have changed perspectives on which genes affect resistance and how the spread of resistant clones happens. Moreover, genomics can provide key evidence of the relationship between similar resistance genes in different pathogens, which is pivotal when rolling out new diagnostic methods. However, as with traditional surveillance systems, the long-term reliability of the data depends on the quality of data collection. Overall, genomic epidemiology has great potential not only in providing additional evidence of how resistant strains emerge, establish, and spread, but also offers an opportunity to improve the quality of surveillance at the population level and is a valuable tool for monitoring and delivering more appropriate antimicrobial prescribing policies. It will also be instrumental in the development, validation, and rollout of new antimicrobial diagnostic tests. A paradigm shift in clinical diagnostic standards could be achieved through the routine integration of next-generation sequencing pipelines, the provision of enriched information about the resistome and the microbiome of clinical samples, and the linking of data generated by different diagnostic services with genomic data, including reference databases [13, 14].

PRECISION MEDICINE AND GENOMICS IN INFECTIOUS DISEASE TREATMENT

A fundamental concept underlying the development of genomics is the move away from a one-size-fits-all approach to precision medicine. This treatment model tailors an individual's health care by using data unique to them, such as genomics, socioeconomic status, environment, and lifestyle. In the realm of infectious diseases, genomics has great potential to inform treatment strategies. Although public health initiatives have excelled in controlling many infectious diseases at the population level, individual treatments are often ineffective or result in side effects. In many cases, pathogens that can cause infections, such as parasites, bacteria, or fungi, vary in the way they present in each host. This makes it difficult for researchers to explore targetable features in broad, unselected populations [5, 15]. Precision medicine based on pathogen genomics can determine a treatment strategy unique to a specific host. Using these genomics, especially when combined with the host DNA of the patient, can increase therapeutic success both by decreasing the potential for mechanism-based treatments in the patient and by reducing future chances for the development of drug resistance. For an increasing number of conditions, particularly cancer, genomics is providing in-depth clinical information that is improving patient outcomes through alternative or combination therapies. Implementation of precision medicine is still in its infancy; however, due to high costs and ethical considerations, clinicians need to be trained in genomics to understand specific therapeutic recommendations. The ethical considerations of using the genetic information of the person to explain the path of pathogens in the treatment strategy have yet to be resolved. Ethical considerations include the capacity for patients to understand and discuss findings and insurance providers to explore new policies to cover these testing modalities. Data sharing is also a limitation in this case because there is no centralized bank of genomics-based treatment plans spanning the breadth of infectious diseases for potential treatments. Currently, treatment modalities are mainly shared through communication between genomics researchers who find them and the clinicians who may benefit from them. The future role of genomics in infectious diseases will also include aiding in the development of vaccines and targeted response strategies in the event of pandemics. Ultimately, the role of genomics in infectious disease is redefining precision medicine at the individual level [16, 17].

CONCLUSION

Genomics has become an indispensable tool in the fight against infectious diseases. From rapidly identifying pathogens to tracking their transmission and aiding in the development of targeted treatments, genomics has transformed our approach to disease control. The integration of genomic data into public health initiatives has enhanced outbreak response, improved antimicrobial resistance monitoring, and paved the way for precision medicine. However, challenges remain, particularly in resource-limited settings, where access to genomic technologies is restricted. Addressing these barriers will be essential for maximizing the global impact of genomics in infectious disease control, offering hope for more effective management of future outbreaks and pandemics.

REFERENCES

1. Hilt EE, Ferrieri P. Next generation and other sequencing technologies in diagnostic microbiology and infectious diseases. Genes. 2022 Aug 31;13(9):1566.
2. Eckhardt M, Hultquist JF, Kaake RM, Hüttenhain R, Krogan NJ. A systems approach to infectious disease. Nature Reviews Genetics. 2020 Jun;21(6):339-54. nih.gov
3. Hill V, Ruis C, Bajaj S, Pybus OG, Kraemer MU. Progress and challenges in virus genomic epidemiology. Trends in Parasitology. 2021 Dec 1;37(12):1038-49.
4. Inzaule SC, Tessema SK, Kebede Y, Ouma AE, Nkengasong JN. Genomic-informed pathogen surveillance in Africa: opportunities and challenges. The Lancet Infectious Diseases. 2021 Sep 1;21(9):e281-9. thelancet.com
5. Kwok AJ, Mentzer A, Knight JC. Host genetics and infectious disease: new tools, insights, and translational opportunities. Nature Reviews Genetics. 2021 Mar;22(3):137-53.
6. Dai X, Shen L. Advances and trends in omics technology development. Frontiers in Medicine. 2022 Jul 1;9:911861.
7. Pérez-Losada M, Arenas M, Galán JC, Bracho MA, Hillung J, García-González N, González-Candelas F. High-throughput sequencing (HTS) for the analysis of viral populations. Infection, Genetics and Evolution. 2020 Jun 1;80:104208.
8. Tedersoo L, Albertsen M, Anslan S, Callahan B. Perspectives and benefits of high-throughput long-read sequencing in microbial ecology. Applied and environmental microbiology. 2021 Aug 11;87(17):e00626-21. asm.org
9. Pollett S, Fauver JR, Maljkovic Berry I, Melendrez M, Morrison A, Gillis LD, Johansson MA, Jarman RG, Grubaugh ND. Genomic epidemiology as a public health tool to combat mosquito-borne virus outbreaks. The Journal of Infectious Diseases. 2020 Mar 28;221(Supplement_3):S308-18. nih.gov
10. Aggarwal D, Warne B, Jahun AS, Hamilton WL, Fieldman T, Du Plessis L, Hill V, Blane B, Watkins E, Wright E, Hall G. Genomic epidemiology of SARS-CoV-2 in a UK university identifies dynamics of transmission. Nature Communications. 2022 Feb 8;13(1):751. nature.com

11. Struelens MJ, Ludden C, Werner G, Sintchenko V, Jokelainen P, Ip M. Real-time genomic surveillance for enhanced control of infectious diseases and antimicrobial resistance. Frontiers in Science. 2024 Apr 25;2:1298248. frontiersin.org
12. Hawken SE, Yelin RD, Lolans K, Weinstein RA, Lin MY, Hayden MK, Snitkin ES. Threshold-free genomic cluster detection to track transmission pathways in healthcare settings. **The Lancet. Microbe**, 05 Jul 2022, 3(9):e652-e662
13. Pruden A, Vikesland PJ, Davis BC, de Roda Husman AM. Seizing the moment: now is the time for integrated global surveillance of antimicrobial resistance in wastewater environments. Current Opinion in Microbiology. 2021 Dec 1;64:91-9. sciencedirect.com
14. Duggett N, AbuOun M, Randall L, Horton R, Lemma F, Rogers J, Crook D, Teale C, Anjum MF. The importance of using whole genome sequencing and extended spectrum beta-lactamase selective media when monitoring antimicrobial resistance. Scientific Reports. 2020 Nov 16;10(1):19880. nature.com
15. Olatunji AO, Olaboye JA, Maha CC, Kolawole TO, Abdul S. Next-Generation strategies to combat antimicrobial resistance: Integrating genomics, CRISPR, and novel therapeutics for effective treatment. Engineering Science & Technology Journal. 2024;5(7):2284-303. researchgate.net
16. Lange C, Aarnoutse R, Chesov D, Van Crevel R, Gillespie SH, Grobbel HP, Kalsdorf B, Kontsevaya I, van Laarhoven A, Nishiguchi T, Mandalakas A. Perspective for precision medicine for tuberculosis. Frontiers in immunology. 2020 Oct 8;11:566608.
17. Wu J, Tang B, Tang Y. Allele-specific genome targeting in the development of precision medicine. Theranostics. 2020;10(7):3118.

CITE AS: Nyiramana Mukamurera P. (2024). The Role of Genomics in Infectious Disease Control. RESEARCH INVENTION JOURNAL OF PUBLIC HEALTH AND PHARMACY 3(2):49-52. https://doi.org/10.59298/RIJPP/2024/3234952